Adage Capital Partners’s Gracell Biotechnologies Inc. American Depositary Shares GRCL Stock Holding History

Adage Capital Partners’s Portfolio GRCL Stock Details GRCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,350,000	Closed	-$13.6M	–	972
2023 Q4	$13.6M	Buy	1,350,000 +500,000	+59%	+$2.27M	0.03%	532
2023 Q3	$2.45M	Buy	+850,000	New	+$3.11M	0.01%	730

Adage Capital Partners's GRCL Position: Q1 2024 in Review

Adage Capital Partners sold out of Gracell Biotechnologies Inc. American Depositary Shares (GRCL) in Q1 2024, closing a stake of 1,350,000 shares — an estimated $13.6M sold.

Adage Capital Partners first reported a position in GRCL in Q3 2023 and held it in 2 quarters. The position peaked at $13.6M in Q4 2023. 0 funds tracked by Wall St. Rank hold GRCL as of Q1 2024.

Adage Capital Partners reported no remaining Gracell Biotechnologies Inc. American Depositary Shares position as of Q1 2024 after selling out during the quarter.
Adage Capital Partners sold 1,350,000 Gracell Biotechnologies Inc. American Depositary Shares shares in Q1 2024, an estimated $13.6M.
Adage Capital Partners first reported a position in Gracell Biotechnologies Inc. American Depositary Shares in Q3 2023 and held it in 2 quarters.
Adage Capital Partners's Gracell Biotechnologies Inc. American Depositary Shares position peaked at $13.6M in Q4 2023.
0 funds tracked by Wall St. Rank held Gracell Biotechnologies Inc. American Depositary Shares as of Q1 2024.

Based on Adage Capital Partners's 13F filing for Q1 2024, filed 15 May 2024.